Clinical Frontier SARMs Series: Innovative Research Tools Advancing Muscle Disease Treatments
In the pharmaceutical and biomedical research fields, clinical frontier SARMs (such as PF-06260414, GSK-2881078, and GLPG0492), as selective androgen receptor modulators that have entered clinical trials, represent potential breakthroughs in treating muscle wasting and metabolic diseases. PHMO is committed to supplying the highest purity cutting-edge research materials, supporting your innovative R&D projects and facilitating the transition from lab to clinic.
With the rising incidence of muscle-related disorders such as sarcopenia, cancer cachexia, and genetic muscular dystrophies, developing safe and effective treatments has become an urgent need. Traditional androgen therapies offer efficacy but often come with cardiovascular risks and prostate side effects. Clinical frontier SARMs, based on advanced molecular design, have progressed to human clinical trials, demonstrating higher safety and efficacy potential. These compounds provide precise muscle protection mechanisms by selectively modulating the androgen receptor, aiding researchers in exploring novel therapies. As experimental compounds, these products are for laboratory use only and not for medical purposes.
1. Function & Core Research Applications
l PF-06260414 (CAS 1612755-71-1)
Developed by Pfizer, PF-06260414 is an oral non-steroidal SARM evaluated in Phase I clinical trials for muscle wasting and age-related sarcopenia. Preclinical studies show high affinity and tissue selectivity, primarily activating muscle tissue to promote protein synthesis and growth while minimizing impact on non-target tissues like the prostate. It is mainly used in animal models for cancer-related muscle wasting and early human safety studies. Clinical data indicate a dose range of 1-100 mg/day with good tolerability, for research reference only.
l GSK-2881078（CAS: 1539314-06-1）
Developed by GSK, GSK-2881078 is an oral SARM that has entered Phase II clinical trials, focusing on muscle wasting associated with chronic obstructive pulmonary disease (COPD) and cancer cachexia. Research demonstrates potent muscle-building effects while maintaining bone density. In clinical trials, doses such as 0.5-2 mg/day improve muscle function and quality of life, highlighting its potential in metabolic diseases. Primarily used in preclinical and clinical models to explore muscle protection mechanisms.
l GLPG0492（CAS: 1215085-92-9）
Developed by Galapagos, GLPG0492 is an oral SARM in Phase I/II clinical trials for Duchenne muscular dystrophy (DMD) and other genetic muscle diseases. Preclinical animal models show enhanced muscle strength and endurance, with reduced fat accumulation. Clinical data support its safety and preliminary efficacy, mainly for research in pediatric and adult degenerative muscle conditions.
Note: Products supplied by PHMO are for in vitro or preclinical research use only. Not for human use.
2. Differentiating Features & Advantages
Compared to early prototype compounds (like the LGD series), these clinical frontier SARMs are designed with greater emphasis on human clinical applicability, featuring optimized pharmacokinetics and safety profiles. PF-06260414 highlights rapid onset and low-dose efficacy, reducing cardiovascular risks; GSK-2881078 uniquely integrates anti-inflammatory mechanisms, making it more suitable for comprehensive treatment of chronic diseases compared to other SARMs (e.g., RAD140, which focuses on pure muscle growth); GLPG0492 targets genetic pathologies with muscle regeneration support, differentiating it from traditional therapies requiring long-term injections. All three have passed IND (Investigational New Drug) reviews, with clinical data supporting tissue selectivity superior to traditional androgens, aiming to minimize side effects and bring research closer to practical applications.
3. Target Audience & Market Validation
These compounds target pharmaceutical companies, clinical research institutions, and academic labs for advancing drug development in muscle diseases. Market validation is based on published clinical trial results: PF-06260414 has completed Phase I safety assessments; GSK-2881078 shows muscle function improvements in Phase II; GLPG0492 has preliminary efficacy in DMD patients. The global clinical SARMs market is projected to grow rapidly, especially in geriatric medicine and rare diseases, but it is emphasized that they are for research only, not consumer use. PHMO, as a supplier, demonstrates its capability in providing cutting-edge materials through collaborations with leading pharmaceutical enterprises.
Unlocking the frontiers of muscle disease treatments starts with top-tier research materials. PHMO ensures every batch of clinical frontier SARMs products comes with a detailed Certificate of Analysis (COA) to guarantee the accuracy of your research data. Contact us for a quotation, or comment below to share your research needs. PHMO – Your Reliable Research Partner!